U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3921
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    47,514.71
    +826.90 (+1.77%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Sanofi confirms its will supply over 125 millions Pfizer-BioNTech doses to the EU

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

PARIS, Jan 27 (Reuters) - French pharmaceutical giant Sanofi said on Wednesday it had struck an agreement with Germany's BioNTech to supply the European Union with the company's vaccine developed in partnership with U.S. group Pfizer.

In a press release, Sanofi, which announced last month it had to delay the launch of its own vaccine jointly developed with Britain's GlaxoSmithKline, confirmed CEO Paul Hudson's comments to newspaper Le Figaro Wednesday. .

"Sanofi will provide BioNTech access to its established infrastructure and expertise to produce over 125 million doses of COVID-19 vaccine in Europe", Sanofi said in statement.

"Initial supplies will originate from Sanofi's production facilities in Frankfurt from summer of 2021", it added, saying its "priority was to continue to develop its two COVID-19 vaccine candidates". (Reporting by Sudip Kar-Gupta; Writing by Benoit Van Overstraeten; Editing by Shri Navaratnam)